Discover
DMRA
Damora Therapeutics, Inc.
27.09
2 x 19.93
2 x 33.39
bid
ask
+
1.08
4.15%
2 @ 04:00 PM
26.57 -0.52 (1.92%)
| Ytd | 17.73% | |
| 1y | 694.43% |
25.76
day range
28.43
2.45
52 week range
38.33
| Open | 26.10 | Prev Close | 26.01 | Low | 25.76 | High | 28.43 | Mkt Cap | 1.67B |
| Vol | 579.61K | Avg Vol | 501.75K | EPS | -2.68 | P/E | N/A | Forward P/E | -12.52 |
| Beta | 1.48 | Short Ratio | 3.49 | Inst. Own | 91.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 23.83 | 200-d Avg | 21.25 | 1yr Est | 43.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-14 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-18 | 2025-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-11 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-05-28 | Wedbush | Upgrade | Outperform | |
| 2026-04-24 | RBC Capital | Upgrade | Outperform | |
| 2026-03-25 | Evercore ISI Group | Upgrade | Outperform | |
| 2026-02-17 | UBS | Upgrade | Buy |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-03-29 | JARRETT A JENNIFER | Chief Executive Officer | 500.00K | Stock Award(Grant) |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 9.05M | 245.04M | 14.70% |
| 2026-03-30 | Fairmount Funds Management LLC | 8.71M | 236.04M | 14.16% |
| 2026-03-30 | Avoro Capital Advisors LLC | 3.78M | 102.48M | 6.15% |
| 2026-03-30 | Venrock Adviser, LLC | 3.60M | 97.62M | 5.85% |
| 2026-03-30 | FCPM III Services B.V. | 2.44M | 66.13M | 3.97% |
| 2026-03-30 | RA Capital Management, L.P. | 2.40M | 65.00M | 3.90% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.83M | 49.55M | 2.97% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 834.04K | 22.59M | 1.35% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 535.39K | 14.50M | 0.87% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 500.00K | 13.55M | 0.81% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 454.56K | 12.31M | 0.74% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 452.81K | 12.27M | 0.74% |